Discovery of Clinical Candidate 2-((2<i>S</i>,6<i>S</i>)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3′-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor
Xiang‐Yang Ye(Hangzhou Normal University), Jeffrey A. Robl(Bristol-Myers Squibb (Germany)), Shung Wu(Bristol-Myers Squibb (United States)), David K. Leahy(Bristol-Myers Squibb (United States)), Thomas Harrity(Bristol-Myers Squibb (United States)), Ramakrishna Seethala(Bristol-Myers Squibb (United States)), Daniel M. Camac(Bristol-Myers Squibb (United States)), James J. Li(University of Wisconsin–Madison), Frederick Moulin(Bristol-Myers Squibb (United States)), Nathan Morgan(Bristol-Myers Squibb (United States)), Rajasree Golla(Bristol-Myers Squibb (United States)), Joel C. Barrish(Jnana Therapeutics (United States)), Akbar Nayeem(Bristol-Myers Squibb (United States)), Randolph Ponticiello(Bristol-Myers Squibb (United States)), Brad D. Maxwell(Bristol-Myers Squibb (United States)), S. Sheriff(Bristol-Myers Squibb (United States)), Raymond P. Scaringe(Bristol-Myers Squibb (United States)), Lawrence J. Kennedy(Bristol-Myers Squibb (United States)), Bogdan Sleczka(Bristol-Myers Squibb (United States)), Paul E. Morin(Bristol-Myers Squibb (United States)), Bin He(Guiyang Medical University), Joseph R. Taylor(Bristol-Myers Squibb (United States)), John D. DiMarco(Bristol-Myers Squibb (United States)), Vidyhashankar Ramamurthy(Bristol-Myers Squibb (United States)), Zhenqiu Hong(Bristol-Myers Squibb (United States)), David Yoon(Bristol-Myers Squibb (United States)), Stephen P. O’Connor(Bristol-Myers Squibb (United States)), Rachel Zebo(Bristol-Myers Squibb (United States)), Jun Li(Bristol-Myers Squibb (United States)), Mengmeng Wang(Bristol-Myers Squibb (United States)), Haixia Wang(Shanghai Sixth People's Hospital), Yixin Li(Qinghai University), Jianqing Li(Nanjing University of Chinese Medicine), Stephanie Chen(Rutgers, The State University of New Jersey), Zhiwei Guo(Bristol-Myers Squibb (United States)), David A. Gordon(Bristol-Myers Squibb (United States)), Steven J. Walker(Bristol-Myers Squibb (United States)), Ronald L. Hanson(Bristol-Myers Squibb (United States)), Timothy W. Harper(Bristol-Myers Squibb (United States)), Mark Kirby(Bristol-Myers Squibb (United States)), Atsu Apedo(Bristol-Myers Squibb (United States))
Cited by 18
Related Papers
Sirt5 Is a NAD-Dependent Protein Lysine Demalonylase and Desuccinylase
|Science|2011|1.4k
Mutation of the Stargardt Disease Gene ( <i>ABCR</i> ) in Age-Related Macular Degeneration
|Science|1997|878
Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2
|Nature|2007|732
Overview of lethal human coronaviruses
|Signal Transduction and Targeted Therapy|2020|312